Complement as a multifaceted modulator of kidney transplant injury

J Clin Invest. 2014 Jun;124(6):2348-54. doi: 10.1172/JCI72273. Epub 2014 Jun 2.


Improvements in clinical care and immunosuppressive medications have positively affected outcomes following kidney transplantation, but graft survival remains suboptimal, with half-lives of approximately 11 years. Late graft loss results from a confluence of processes initiated by ischemia-reperfusion injury and compounded by effector mechanisms of uncontrolled alloreactive T cells and anti-HLA antibodies. When combined with immunosuppressant toxicity, post-transplant diabetes and hypertension, and recurrent disease, among other factors, the result is interstitial fibrosis, tubular atrophy, and graft failure. Emerging evidence over the last decade unexpectedly identified the complement cascade as a common thread in this process. Complement activation and function affects allograft injury at essentially every step. These fundamental new insights, summarized herein, provide the foundation for testing the efficacy of various complement antagonists to improve kidney transplant function and long-term graft survival.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allografts
  • Animals
  • Complement Activation*
  • Graft Survival / immunology
  • Humans
  • Immunosuppression
  • Kidney / immunology*
  • Kidney / injuries*
  • Kidney / pathology
  • Kidney Transplantation / adverse effects*
  • Models, Immunological
  • Reperfusion Injury / etiology
  • Reperfusion Injury / immunology
  • T-Lymphocytes / immunology